MIM
MNPR icon

MetLife Investment Management’s Monopar Therapeutics MNPR Stock Holding History

MetLife Investment Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Hold
2,538
– – ﹤0.01% 2391
2025
Q4 		$166K Hold
2,538
– – ﹤0.01% 2363
2025
Q3 		$207K Hold
2,538
– – ﹤0.01% 2297
2025
Q2 		$90.8K Buy
+2,538
New +$92.2K ﹤0.01% 2597

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's MNPR Position: Q1 2026 in Review

MetLife Investment Management held its Monopar Therapeutics (MNPR) position steady in Q1 2026 at 2,538 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

MetLife Investment Management first reported a position in MNPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $207K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • MetLife Investment Management held 2,538 shares of Monopar Therapeutics worth $139K as of Q1 2026.
  • MetLife Investment Management left its Monopar Therapeutics share count unchanged in Q1 2026.
  • Monopar Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2391 holding.
  • MetLife Investment Management first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • MetLife Investment Management's Monopar Therapeutics position peaked at $207K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.